Skip to main content

Role for the left atrial appendage occlusion device in managing thromboembolic risk in atrial fibrillation

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Abstract

Only 50% of patients who would benefit from warfarin therapy for atrial fibrillation (AF) receive treatment because of clinical concerns regarding chronic anti‐coagulation. Percutaneous strategies to treat AF, including pulmonary vein isolation with a curative intent or atrioventricular nodal ablation and implantation of a permanent pacemaker for palliative rate control, have not eliminated the need to manage thromboembolic risk. With the development of a percutaneous left atrial appendage (LAA) occlusion device (the WATCHMAN percutaneous left atrial appendage occluder – Atritech Inc., Plymouth, MN, USA) for thromboembolic protection in non‐valvular AF a significant therapeutic option for select patients may be available. We present the first case performed in Australia (24 November 2009) and explore this new methodology.

Document Type: Research Article

DOI: https://doi.org/10.1111/j.1445-5994.2011.02698.x

Affiliations: Monash Cardiovascular Research Centre, Monash Heart and Monash University Department of Medicine, Southern Health Network, Melbourne, Victoria, Australia

Publication date: 2012-03-01

  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more